Can an arthritis drug tame a rare bone marrow cancer?

NCT ID NCT05467800

Ongoing Disease control Sponsor: John Mascarenhas Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests canakinumab, an anti-inflammatory drug, in 14 to 26 people with myelofibrosis, a rare bone marrow cancer that causes scarring, enlarged spleen, and fatigue. Participants receive injections every three weeks for about six months. The study checks if the drug can shrink the spleen, improve blood counts, and ease symptoms, while also monitoring side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: canakinumab (an anti-inflammatory drug given as a shot under the skin)
What this could lead to: If it works, this could point toward a new treatment option for myelofibrosis, a rare bone marrow cancer.
What could go wrong: This is a small, early-phase trial with only 14-26 participants, so results may not apply to everyone. The drug may not work or could cause side effects like infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ET-MF are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera essential thrombocythemia primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ET-MF POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS POST-POLYCYTHEMIA VERA RELATED MYELOFIBROSIS PRIMARY MYELOFIBROSIS PV-MF

Contacts and locations

Locations

Atrium Health Levine Cancer Institute

Charlotte, North Carolina, 28204, United States
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute

Los Angeles, California, 90048, United States
Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
Ruttenberg Treatment Center

New York, New York, 10029, United States
The University of Kansas Cancer Center-Westwood

Westwood, Kansas, 66205, United States
Wake Forest Baptist Health Comprehensive Cancer Center

Winston-Salem, North Carolina, 27157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.